Scottoni Federico, Fusaro Fabio, Conforti Andrea, Morini Francesco, Bagolan Pietro
Medical and Surgical Neonatology, Bambino Gesù Children's Hospital, Rome, Italy.
Medical and Surgical Neonatology, Bambino Gesù Children's Hospital, Rome, Italy.
J Pediatr Surg. 2015 Oct;50(10):1722-5. doi: 10.1016/j.jpedsurg.2015.03.069. Epub 2015 Apr 28.
Refractory chylothorax is a severe clinical issue, particularly in neonates. Conventional primary approach is based on diet with medium-chain fatty acids and/or total parenteral nutrition. In nonresponders, proposed second line treatments include chemical or surgical pleurodesis, thoracic duct ligation, pleuroperitoneal shunting and pleurectomy but none of these have been shown to be superior to other in terms of resolution rate and safety. Our aim is to report our experience on povidone-iodine use for chemical pleurodesis in newborn infants with chylothorax unresponsive to conservative treatment. Our aim is to report our experience on povidone-iodine use for chemical pleurodesis in newborn infants with chylothorax unresponsive to conservative treatment.
Since 2013, povidone-iodine pleurodesis was attempted in all patients with persistent chylothorax who failed conservative treatment (no response to at least 10 days of total parenteral nutrition and maximum dosage of intravenous octreotide). Pleurodesis consisted in the injection of 2 ml/kg of a 4% povidone-iodine solution inside the pleural space, leaving the pleural tube clamped for the subsequent 4 hours.
Five patients were treated with chemical pleurodesis of persistent chylothorax. Four of 5 patients had their pleural effusion treated by one single povidone-iodine infusion. Median time for resolution was 4 days. A patient with massive superior vena cava thrombosis did not benefit from pleurodesis. None of the patients experienced long term side effects of the treatment.
Our data suggest that povidone-iodine pleurodesis may be considered a safe and effective option to treat refractory chylothorax in newborns.
难治性乳糜胸是一个严重的临床问题,在新生儿中尤为突出。传统的主要治疗方法是采用含中链脂肪酸的饮食和/或全胃肠外营养。对于无反应者,建议的二线治疗包括化学或手术性胸膜固定术、胸导管结扎术、胸膜腹膜分流术和胸膜切除术,但在治愈率和安全性方面,这些方法均未显示出优于其他方法。我们的目的是报告我们在使用聚维酮碘对保守治疗无反应的新生儿乳糜胸进行化学胸膜固定术方面的经验。我们的目的是报告我们在使用聚维酮碘对保守治疗无反应的新生儿乳糜胸进行化学胸膜固定术方面的经验。
自2013年以来,对所有保守治疗失败(对至少10天的全胃肠外营养和最大剂量的静脉注射奥曲肽无反应)的持续性乳糜胸患者尝试进行聚维酮碘胸膜固定术。胸膜固定术包括在胸膜腔内注射2 ml/kg的4%聚维酮碘溶液,随后4小时夹闭胸膜管。
5例患者接受了持续性乳糜胸的化学胸膜固定术治疗。5例患者中有4例通过单次聚维酮碘输注治疗胸腔积液。积液消退的中位时间为4天。1例患有大量上腔静脉血栓形成的患者未从胸膜固定术中获益。所有患者均未出现该治疗的长期副作用。
我们的数据表明,聚维酮碘胸膜固定术可被视为治疗新生儿难治性乳糜胸的一种安全有效的选择。